84358-12-3

Basic information

• Product Name: 1-Boc-3-piperidinecarboxylic acid
• Synonyms: N-BOC-DL-NIPECOTIC ACID;(+/-)-N-BOC-NIPECOTIC ACID;N-BOC-NIPECOTIC ACID;(+/-)-N-BOC-PIPERIDINE-3-CARBOXYLIC ACID;N-BOC-PIPERIDINE-3-CARBOXYLIC ACID;N-ALPHA-T-BOC-3-CARBOXYPIPERIDINE;N-T-BUTOXYCARBONYL-DL-NIPECOTIC ACID;N-T-BUTOXYCARBONYL-DL-3-PIPERIDINECARBOXYLIC ACID
• CAS NO: 84358-12-3
• Molecular Formula: C₁₁H₁₉NO₄
• Molecular Weight: 229.27
• Product Categories: Carboxylic Acids;Pyrans, Piperidines &Piperazines;Piperidine;API intermediates;Piperidines;Carboxylic Acids;Pyrans, Piperidines & Piperazines;Others;Peptide Synthesis;Unnatural Amino Acid Derivatives
• Mol File: 84358-12-3.mol
• Article Data: 42

Chemical Properties

• Melting Point: 159-162 °C(lit.)
• Boiling Point: 353.2 °C at 760 mmHg
• Flash Point: 167.4 °C
• Appearance: White/Crystalline Powder
• Density: 1.164 g/cm³
• Storage Temp.: Store at 0-5°C
• PKA: 4.49±0.20(Predicted)
• BRN: 5539297
• CAS DataBase Reference: 1-Boc-3-piperidinecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-3-piperidinecarboxylic acid(84358-12-3)
• EPA Substance Registry System: 1-Boc-3-piperidinecarboxylic acid(84358-12-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 84358-12-3(Hazardous Substances Data)

Usage

Chemical Properties

White crystalline powder

Upstream product

• 148672-74-6 ethyl N-(t-butyloxycarbonyl)nipecotate 
• 123-91-1 1,4-dioxane 
• 498-95-3 nipecotic acid 
• 851956-01-9 (S)-(+)-3-piperidinecarboxylic acid hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 59-67-6 nicotinic acid 
• 73371-96-7 2-<<(tert-butoxycarbonyl)oxy>imino>-2-phenylacetonitrile 
• 121-44-8 triethylamine 
• 114214-69-6 tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 71962-74-8 Ethyl nipecotate 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 

Downstream Products

• 744221-50-9 3-(4-hexyloxy-benzylcarbamoyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 676259-95-3 piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-(2,6-diisopropyl-phenyl) ester 
• 183207-70-7 3(R)-Benzyloxycarbonylamino-piperidine-1-carboxylic acid tert-butyl ester 
• 414867-35-9 1-(1-tert-butoxycarbonylpiperidine-3-carbonyl)-piperidine-2-carboxylic acid [4-phenyl-1-(3-phenyl-propyl)-butyl]-amide 
• 189442-78-2 (±)-tert-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate 
• 139985-95-8 piperidine-1,3-dicarboxylic acid 3-benzyl ester 1-tert-butyl ester 
• 876147-55-6 1-(tert-Butoxycarbonyl)-N-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methyl]piperidine-3-carboxamide 
• 189321-64-0 C₁₁H₁₈N₂O₃ 
• 959236-11-4 3-allylpiperidine-1,3-dicarboxylic acid 1-tert-butyl ester 
• 1031340-47-2 C₃₇H₄₇FN₄O₆ 
• 911367-45-8 tert-butyl 3-[(3S)-3-(3-{[(benzyloxy)carbonyl]amino}propyl)-5-(2-hydroxyethyl)-4,9-dioxo-11-phenyl-10-oxa-2,5,8-triazaundecan-1-oyl]piperidine-1-carboxylate 
• 868284-37-1 3-(2-acetylphenyl)-1-tert-butyl piperidine-1,3-dicarboxylate 
• 873566-64-4 4-{3-[(N-tert-butoxycarbonylpiperidin-3-yl)carbonylamino]phenyl}-2-chloro-6-morpholinopyrimidine 

Relevant articles and documents

Design, Synthesis and Enhanced BBB Penetration Studies of L-serine-Tethered Nipecotic Acid-Prodrug

Nipecotic acid is considered to be one of the most potent inhibitors of neuronal and glial-aminobutyric acid (GABA) uptake in vitro. Due to its hydrophilic nature, nipecotic acid does not readily cross the blood-brain barrier (BBB). Large neutral amino acids (LAT1)-knotted nipecotic acid prodrug was designed and synthesized with the aim to enhance the BBB permeation by the use of carrier-mediated transport. The synthesized prodrug was tested in animal models of Pentylenetetrazole (PTZ)-induced convulsions in mice. Further pain studies were carried out followed by neurotoxicity estimation by writhing and rota-rod test respectively. HPLC data suggests that the synthesized prodrug has improved penetration through BBB. Nipecotic acid-L-serine ester prodrug with considerable anti-epileptic activity, and the ability to permeate the BBB has been successfully synthesized. Graphical Abstract. Graphical Abstract.

PYRAZOLOPYRIDAZINE DERIVATIVES, PREPARATION METHOD THEREOF AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME

The present invention is a pyrazolopyridazine derivative. A pharmaceutical composition for preventing or treating cancer contains the pyrazolopyridazin derivative compound Hsp90 according to the present invention as an active ingredient, which can be used as Hsp90 a pharmaceutical composition for preventing or treating Hsp90-related diseases such as melanoma, brain tumor, breast cancer, lung cancer and the like. (by machine translation)

Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B

The resurgence of interest in monoamine oxidases (MAOs) has been fueled by recent correlations of this enzymatic activity with cardiovascular, neurological, and oncological disorders. This has promoted increased research into selective MAO-A and MAO-B inhibitors. Here, we shed light on how selective inhibition of MAO-A and MAO-B can be achieved by geometric isomers of cis-and trans-1-propargyl-4-styrylpiperidines. While the cis isomers are potent human MAO-A inhibitors, the trans analogues selectively target only the MAO-B isoform. The inhibition was studied by kinetic analysis, UV-vis spectrum measurements, and X-ray crystallography. The selective inhibition of the MAO-A and MAO-B isoforms was confirmed ex vivo in mouse brain homogenates, and additional in vivo studies in mice show the therapeutic potential of 1-propargyl-4-styrylpiperidines for central nervous system disorders. This study represents a unique case of stereoselective activity of cis/trans isomers that can discriminate between structurally related enzyme isoforms.